Conditions: Rosacea Erythema
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 357
Healthy volunteers: no

Brief summary:
This study will evaluate the safety and efficacy of 3 doses of AGN-199201 once and twice daily compared to vehicle for the treatment of moderate to severe facial erythema associated with rosacea.

Detailed description:

Arms:
arm 1: AGN-199201 Dose A applied once daily to the face for 28 days. arm 2: AGN-199201 Dose B applied once daily to the face for 28 days. arm 3: AGN-199201 Dose C applied once daily to the face for 28 days. arm 4: AGN-199201 Vehicle applied once daily to the face for 28 days. arm 5: AGN-199201 Dose A applied twice daily to the face for 28 days. arm 6: AGN-199201 Dose B applied twice daily to the face for 28 days. arm 7: AGN-199201 Dose C applied twice daily to the face for 28 days. arm 8: AGN-199201 Vehicle applied twice daily to the face for 28 days.

Interventions: intervention 1: AGN-199201 Dose A intervention 2: AGN-199201 Dose B intervention 3: AGN-199201 Dose C intervention 4: AGN-199201 Vehicle
Intervention descriptions: intervention 1: AGN-199201 Dose A applied once or twice daily to the face for 28 days. intervention 2: AGN-199201 Dose B applied once or twice daily to the face for 28 days. intervention 3: AGN-199201 Dose C applied once or twice daily to the face for 28 days. intervention 4: AGN-199201 Vehicle applied once or twice daily to the face for 28 days.

Protocol document: